Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis

Introduction: Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinical trials for applicability in daily clinical practice. Although some studies have reported real-world evidence of UST, only few studies have confirmed its effectiveness in the real world. The aim of this study was to assess the short- and long-term effectiveness, durability, safety, and risk factors for discontinuation of UST in UC in clinical practice. Methods: This was a retrospective, single-center, observational study. From March 2020 to January 2023, all consecutive patients with active UC who were treated with UST at Nagoya University Hospital were included. The primary outcome was the clinical remission rate at weeks 2–8 and weeks 24–48. The secondary outcomes included clinical response, persistence of UST therapy, endoscopic changes during follow-up, risk factors for UST discontinuation, and occurrence of any adverse events. The clinical effectiveness was evaluated using the Lichtiger score. Results: A total of 31 patients were included in this study. The clinical remission rates were 9.7%, 29.0%, 54.8%, and 64.5% at weeks 2, 8, 24, and 48, respectively. Twelve (38.7%) patients discontinued UST during the follow-up period. The probability of continuing UST was 93.5%, 80.6%, 77%, and 70% at weeks 2, 8, 24, and 48, respectively. The major reason for discontinuation of UST was primary failure (75.0%). A high baseline C-reactive protein (CRP) level was a significant risk factor for the discontinuation of UST. No adverse events were observed in this study. Conclusion: UST is effective for patients with UC. High CRP levels were identified as a risk factor for UST discontinuation. The findings of this study would help clinicians to select appropriate treatment options for patients with UC by identifying the risk factors for treatment discontinuation.

Angaben zum Objekt

• Standort: Deutsche Nationalbibliothek Frankfurt am Main
• Umfang: Online-Ressource
• Sprache: Englisch

Verweise und Beziehungen

• Erschienen in: Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis ; volume:8 ; number:2 ; year:2023 ; pages:60-68 ; extent:9 ; Inflammatory intestinal diseases ; 8, Heft 2 (2023), 60-68 (gesamt 9)

Beteiligte, Orts- und Zeitangaben

• Urheber: Uchida, Genta ; Nakamura, Masanao ; Yamamura, Takeshi ; Maeda, Keiko ; Sawada, Tsunaki ; Ishikawa, Eri ; Furukawa, Kazuhiro ; Iida, Tadashi ; Mizutani, Yasuyuki ; Yamao, Kentaro ; Ishikawa, Takuya ; Ishizu, Yoji ; Honda, Takashi ; Ishigami, Masatoshi ; Kawashima, Hiroki

Weitere Informationen

• DOI: 10.1159/000531497
• URN: urn:nbn:de:101:1-2023101900202209490240
• Rechteinformation: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Letzte Aktualisierung: 22.01.0008, 09:44 MEZ